The pharmaceutical industry is adapting and evolving rapidly, particularly in how pharma medicines and drug products reach patients. Multiple digital channels are emerging – from online pharmacies and e-commerce platforms to direct-to-patient (D2P) models, and even social media marketplaces. According to research firm The Insight Partners, the US digital pharmaceutical market is projected to reach a value of $240 billion by 2030, at a strong compound annual growth rate of 17.25%.

Around the globe, this digital transformation is taking different forms. Traditional pharmacies are expanding into e-commerce, while platforms like Amazon are entering the pharmaceutical space. Notably, some major pharmaceutical companies are developing their own D2P platforms, which enable them to control and monitor the complete supply chain from manufacture to patient delivery.

D2P models differ from digital pharmacies, which act as online resellers of pharmaceutical products. Both models continue to grow as healthcare systems embrace more efficient delivery methods. While they’re different in approach, all these channels offer patients greater convenience, time savings and potentially lower costs compared to traditional brick-and-mortar pharmacies.

However, this proliferation of digital channels brings new security considerations, especially for packaging design. While online platforms offer unprecedented convenience and accessibility, they also create opportunities for counterfeiters. The European Intellectual Property Office (EUIPO) reports that across the European Union, counterfeit medicines account for up to 2% of total sales, costing the pharmaceutical industry an estimated €10.2 billion annually. This risk is amplified in digital spaces where visual verification of security features isn’t possible pre-purchase.

The anonymity of online platforms has created new opportunities for counterfeiters to infiltrate the pharmaceutical supply chain. With two-thirds of countries lacking specific regulations for online pharmaceutical sales, criminal operations could easily establish global distribution networks for counterfeit medicines. High-value segments like women’s health products and anti-obesity medications, the latter projected to reach $44 billion by 2030, are particularly vulnerable targets.

While digital platforms offer consumers broader access to medicines, this expanded choice comes with heightened risks. Without the ability to physically inspect packaging security features before purchase, patients may unknowingly receive dangerous counterfeit products that appear genuine. This not only endangers public health but also threatens consumer confidence in legitimate pharmaceutical channels.

In addition, when medicines are supplied to patients through digital channels, the role of packaging in communication becomes paramount. Without face-to-face guidance from healthcare professionals, clear and comprehensive on-pack information and patient leaflets must bridge this gap. Packaging design needs to account for this shift by ensuring all usage instructions, safety information and adherence guidance is presented in an accessible, easy-to-understand format. For international pharma businesses, this also means access to multilingual instructions, supporting patient adherence.

Looking ahead, continued growth in digital pharmacy adoption is anticipated across both the US and European markets. Development teams are already working on next-generation solutions that will further enhance supply chain security while supporting efficient digital distribution models. The key to success lies in proactive adaptation.